Answers are grounded in this paper and cite their sources.
Asthma involves variable airflow limitation, chronic airway inflammation and, in some patients, persistent airway-wall remodeling. YAP and TAZ are transcriptional coactivators regulated by Hippo kinases and by actin-dependent mechanical inputs. This review distinguishes observations in human asthma specimens from mechanistic findings in cultured cells and allergen- or chemical-exposure animal models. In human asthma specimens and HDM-exposed mouse lungs, nuclear YAP staining in alveolar type II cells was associated with CTGF production and myofibroblast accumulation. Experimental Treg studies implicate Notch4-associated Hippo and Wnt signaling in impaired suppressive activity and type 17 or type 2 inflammatory responses; airway smooth-muscle experiments connect YAP dephosphorylation and nuclear localization to proliferative and migratory programs. A separate TDI-exposure model implicates mitochondrial ROS, β-catenin destruction-complex stability and YAP1 in epithelial inflammatory responses. These mechanisms differ by cell type and model, and do not establish a common pathway in all asthma phenotypes. Pharmacological studies remain preclinical for asthma; verteporfin and other upstream modulators are not selective probes of YAP/TEAD activity. Future work should test pathway dependence using cell-specific genetic and pharmacological approaches and relate molecular readouts to airway function.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: